Lymphopenia: A new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma

To determine overall survival (OS) and independent prognostic factors in patients with brain metastases (BM) from breast cancer treated by whole brain radiotherapy (WBR). One hundred and twenty (120) women with BM, treated in a single French cancer center between 02/91 and 06/01, were reviewed. BM w...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2005-09, Vol.76 (3), p.334-339
Main Authors: Claude, Line, Perol, David, Ray-Coquard, Isabelle, Petit, Thierry, Blay, Jean-Yves, Carrie, Christian, Bachelot, Thomas
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomarkers - analysis
Brain Neoplasms - radiotherapy
Brain Neoplasms - secondary
Breast neoplasms
Breast Neoplasms - complications
Breast Neoplasms - pathology
Carcinoma - complications
Carcinoma - pathology
Cranial irradiation
Female
Humans
Karnofsky Performance Status
Lymphopenia - etiology
Lymphopenia - pathology
Middle Aged
Multivariate Analysis
Prognosis
Risk Factors
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine overall survival (OS) and independent prognostic factors in patients with brain metastases (BM) from breast cancer treated by whole brain radiotherapy (WBR). One hundred and twenty (120) women with BM, treated in a single French cancer center between 02/91 and 06/01, were reviewed. BM were confirmed by computed tomography or magnetic resonance imaging. Survival time was defined as the time interval from the date of BM to the date of death or last follow-up. A Cox proportional hazards regression model was used to determine significant prognostic factors in a multivariate analysis. Surgery was followed by WBR in 5 patients. One hundred and four (104) patients received exclusive WBR, eight received concomitant chemo-radiation, and one received chemo-radiation after surgery. The median survival time was 5 months (95% CI: 3–7 months). In the multivariate analysis, performance status over 1 and lymphopenia (
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2005.06.004